Patents Assigned to UCB Biopharma SPRL
-
Patent number: 9926313Abstract: A series of substituted 3H imidazo[4,5-b]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.Type: GrantFiled: December 8, 2014Date of Patent: March 27, 2018Assignee: UCB BIOPHARMA SPRLInventors: Michael Louis Robert Deligny, Jag Paul Heer, Victoria Elizabeth Jackson, Boris Kroeplien, Fabien Claude Lecomte, John Robert Porter
-
Patent number: 9920052Abstract: A series of substituted 1H imidazo[4,5-c]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.Type: GrantFiled: December 8, 2014Date of Patent: March 20, 2018Assignee: UCB Biopharma SPRLInventors: Victoria Elizabeth Jackson, John Robert Porter
-
Patent number: 9908939Abstract: The present invention relates to an anti-CSF-1R antibody and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The present invention also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment.Type: GrantFiled: August 26, 2014Date of Patent: March 6, 2018Assignee: UCB BIOPHARMA SPRLInventors: Graham Craggs, Karine Jeannine Madeleine Hervé, Diane Marshall
-
Patent number: 9902768Abstract: The present disclosure provides an asymmetric mixed antibody comprising two heavy chains or heavy chain fragments each comprising at least a variable region, a hinge region and a CH1 domain, wherein a first heavy chain or fragment thereof is a class IgG4 and has: a the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the CH1 domain is substituted with another amino acid; and b optionally one or more of the amino acids positioned in the upper hinge region is substituted with cysteine, and wherein the second heavy chain or fragment thereof is characterized in that part or all of the chain has a different amino acid sequence to said first heavy chain in at least the region outside the variable region (for example the constant region), formulations comprising the same, therapeutic used of both of the above, and processes for preparing the antibodies and formulation.Type: GrantFiled: February 22, 2013Date of Patent: February 27, 2018Assignee: UCB BIOPHARMA SPRLInventors: David Paul Humphreys, Shirley Jane Peters
-
Patent number: 9902720Abstract: A series of substituted pyrazolo[1,5-a]pyridine derivatives, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.Type: GrantFiled: December 8, 2014Date of Patent: February 27, 2018Assignee: UCB BIOPHARMA SPRLInventors: Daniel Christopher Brookings, Victoria Elizabeth Jackson, Boris Kroeplien
-
Patent number: 9901673Abstract: Provided is a cassette unit suitable for use with an auto-injector having an electrically powered drive unit. The cassette unit has a housing defining a cassette unit housing cavity and a needle projection aperture. The housing cavity is arranged for receipt of a syringe suitable for delivery of a drug to a patient. The syringe has a barrel for containing a volume of a liquid drug formulation, the barrel defining a flange at the rear end thereof and a forward shoulder at the forward end thereof. The cassette unit includes one or more shoulder support features for supporting the forward shoulder of the syringe. In use, the one or more shoulder support features act to direct a major part of an applied load path to travel through the shoulder at the forward end of the syringe and lesser load to pass through the flange at the rear end thereof.Type: GrantFiled: June 4, 2012Date of Patent: February 27, 2018Assignee: UCB BIOPHARMA SPRLInventors: Martin John McLoughlin, Kevin Richard Lozeau, Agnete Enga, Eric Freitag, Daniel Formosa, Michael Schumann, Brian Lipford, Jake Cowperthwaite, Alex Flamm, Ilario Melzi
-
Patent number: 9901686Abstract: The syringe systems disclosed herein provide in part devices for allowing patients with compromised joint strength to more easily administer medicine. Certain exemplary syringe embodiments include a handle forming a handgrip, a syringe barrel that magnifies the dosage marks located on an inner barrel, and a tip cap slidably engageable with the syringe barrel for shielding a needle.Type: GrantFiled: October 11, 2013Date of Patent: February 27, 2018Assignee: UCB BIOPHARMA SPRLInventors: Darrell P. Morgan, Alex Lee, Dan Formosa, Steven Vordenberg, Joern Vicari, Eric Freitag, Boris Kontorvich
-
Patent number: 9901674Abstract: Provided is a cassette unit suitable for use with an auto-injector having an electrically powered drive unit. The cassette unit has a housing defining a cassette unit housing cavity and a needle projection aperture. The housing cavity is arranged for receipt of a syringe for injected delivery of a drug to a patient. The cassette unit includes a removable cap that in a capping position fits over and thereby acts to close off the needle projection aperture; and connecting to the removable cap, a needle cover defining a needle sheath for sheathing the needle tip of the syringe. The removable cap is provided with one or more first engagement features arranged for selectively engaging one or more second engagement features of the cassette unit housing when the removable cap is in the capping position to thereby restrict/prevent rotation of the removable cap and needle cover relative to the housing.Type: GrantFiled: June 4, 2012Date of Patent: February 27, 2018Assignee: UCB BIOPHARMA SPRLInventors: Martin John McLoughlin, Darrell P. Morgan, Michael James David Heald, Kevin Richard Lozeau, Agnete Enga, Eric Freitag, Daniel Formosa, Michael Schumann, Brian Lipford, Jake Cowperthwaite, Alex Flamm, Ilario Melzi
-
Patent number: 9890154Abstract: A series of substituted 3H-imidazo[4,5-c]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.Type: GrantFiled: December 8, 2014Date of Patent: February 13, 2018Assignee: UCB Biopharma SPRLInventors: Victoria Elizabeth Jackson, Boris Kroeplien, John Robert Porter
-
Patent number: 9890174Abstract: A series of substituted fused tricyclic imidazole derivatives, in particular dihydro-1H-pyrano[4?,3?:4,5]imidazo[1,2-a]pyridine, 1,2,3,4-tetrahydroimidazo[1,2-a:5,4-c?]dipyridine, dihydro-1H-pyrano[3?,4?:4,5]imidazo[1,2-a]pyridine and tetrahydro-6H-cyclohepta[4,5]imidazo[1,2-a]pyridine, and analogs thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.Type: GrantFiled: December 8, 2014Date of Patent: February 13, 2018Assignee: UCB BIOPHARMA SPRLInventors: Rikki Peter Alexander, Julien Alistair Brown, Michael Deligny, Jag Paul Heer, Victoria Elizabeth Jackson, Sophie Jadot, Boris Kroeplien, Malcolm Mac Coss, Yogesh Anil Sabnis, Dominique Louis Léon Swinnen, Nathalie Van Houtvin, Zhaoning Zhu
-
Patent number: 9890219Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.Type: GrantFiled: May 7, 2015Date of Patent: February 13, 2018Assignee: UCB BIOPHARMA SPRLInventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki
-
Publication number: 20180037646Abstract: The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.Type: ApplicationFiled: September 7, 2017Publication date: February 8, 2018Applicant: UCB BIOPHARMA SPRLInventors: Thomas Allen Ceska, Alistair James Henry, Jiye Shi
-
Patent number: 9884152Abstract: Provided is a cassette unit suitable for use with an auto-injector having an electrically powered drive unit. The cassette unit has a housing defining a cassette unit housing cavity and a needle projection aperture. The cassette unit housing cavity is arranged for receipt of a syringe suitable for use in the injected delivery of drug to a patient. The cassette unit includes a needle cover defining a needle sheath. The removable cap is provided with a connector defining one or more needle cover gripping elements for gripping the needle cover. The connector defines a central hub and the one or more needle gripper elements attach to the central hub and in spaced arrangement relative to each other. The connector locates within the removable cap such that the central hub of the connector is in spaced relationship with a far end wall or surface of the cap interior.Type: GrantFiled: June 4, 2012Date of Patent: February 6, 2018Assignee: UCB Biopharma SPRLInventors: Martin John McLoughlin, Darrell P. Morgan, Michael James David Heald, Kevin Richard Lozeau, Agnete Enga, Eric Freitag, Daniel Formosa, Michael Schumann, Brian Lipford, Jake Cowperthwaite, Alex Flamm, Ilario Melzi
-
Patent number: 9878092Abstract: There is provided a cassette unit that is suitable for use with an auto-injector having an electrically powered drive unit. The cassette unit has a housing defining a cassette unit housing cavity and a needle projection aperture. The cassette unit housing cavity is arranged for receipt of a syringe that is suitable for use in the injected delivery of drug to a patient. The cassette unit includes a removable cap that in a capping position fits over and thereby, acts such as to close off, the needle projection aperture. The cassette unit includes a cap lock feature movable from a first cap locking position in which it prevents removal of the removable cap from the capping position with the cassette unit to a second cap non-locking position in which it no longer prevents such cap removal.Type: GrantFiled: June 4, 2012Date of Patent: January 30, 2018Assignee: UCB Biopharma SPRLInventors: Martin John McLoughlin, Darrell P. Morgan, Michael James David Heald, Kevin Richard Lozeau, Agnete Enga, Heather Martin, Eric Freitag, Daniel Formosa, Michael Schumann, Brian Lipford, Jake Cowperthwaite, Alex Flamm, Keith Lipford, Ilario Melzi
-
Publication number: 20180022748Abstract: The invention relates to 9H-pyrrolo-dipyridine derivatives of formula I, processes for preparing them, pharmaceutical compositions containing them and their use as radiopharmaceuticals in particular as imaging agents for the detection of Tau aggregates.Type: ApplicationFiled: January 29, 2016Publication date: January 25, 2018Applicant: UCB Biopharma SPRLInventors: Joel Mercier, Laurent Provins, Celine Vermeiren, Yogesh Anil Sabnis
-
Patent number: 9873703Abstract: A series of substituted imidazo[1,2-b]pyridazine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.Type: GrantFiled: December 8, 2014Date of Patent: January 23, 2018Assignee: UCB BIOPHARMA SPRLInventors: Mezher Hussein Ali, Daniel Christopher Brookings, Julien Alistair Brown, Martin Clive Hutchings, Victoria Elizabeth Jackson, Boris Kroeplien, John Robert Porter, Joanna Rachel Quincey
-
Patent number: 9873735Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.Type: GrantFiled: April 27, 2015Date of Patent: January 23, 2018Assignee: UCB Biopharma SprlInventors: Ralph Adams, Pallavi Bhatta, Sam Philip Heywood, David Paul Humphreys
-
Patent number: 9867941Abstract: Provided is a drive unit for an auto-injector having a drive unit housing arranged for docking receipt of a syringe or of a cassette unit comprising a syringe movable from a rest position, in which a needle tip of the syringe is within the drive unit housing to a use position, in which the needle tip protrudes from a needle delivery aperture; and a drive arrangement including one or more electrically powered sources of axial drive; a first drive transfer element for advancing the syringe to said use position; and a second drive transfer element for moving a plunger into the barrel of the syringe to eject liquid contents thereof. The drive unit housing is provided with a skin sensor arrangement having an array of plural skin sensor electrodes located about the needle delivery aperture.Type: GrantFiled: October 21, 2013Date of Patent: January 16, 2018Assignee: UCB Biopharma SPRLInventors: Martin John McLoughlin, Michael James David Heald, Cameron Townley Charles, Dylan Sanders Garrett, Kevin Richard Lozeau
-
Patent number: 9868749Abstract: A series of substituted benzimidazole, imidazo[1,2-a]pyridine and pyrazolo[1,5-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.Type: GrantFiled: December 8, 2014Date of Patent: January 16, 2018Assignee: UCB BIOPHARMA SPRLInventors: Rikki Peter Alexander, Jonathan Mark Bentley, Gareth Neil Brace, Daniel Christopher Brookings, Prafulkumar Tulshibhai Chovatia, Hervé Jean Claude Deboves, Craig Johnstone, Elizabeth Pearl Jones, Boris Kroeplien, Fabien Claude Lecomte, James Madden, Craig Miller, John Robert Porter, Matthew Duncan Selby, Michael Alan Shaw, Darshan Gunvant Vaidya, Ian Andrew Yule
-
Patent number: 9850240Abstract: A series of substituted [1,2,4]triazolo[4,3-a]pyridine derivatives, being potent modulators of human TNF activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.Type: GrantFiled: December 8, 2014Date of Patent: December 26, 2017Assignee: UCB BIOPHARMA SPRLInventors: Daniel Christopher Brookings, Victoria Elizabeth Jackson